Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | MPI | P34949 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853674 | 0.97 | MAPT (0.52) | ATMMAPTALDH1A1MCL1CES2 | |
| SCHEMBL28164197 | 0.94 | ATM (0.50) | ATMMAPTALDH1A1MCL1CES2 | |
| SCHEMBL485498 | 0.82 | MAPT (0.45) | ATMMAPTALDH1A1MCL1CES2 | |
| SCHEMBL19413742 | 0.80 | MAPT (0.43) | ATMMAPTALDH1A1MCL1CES2 | |
| SCHEMBL9455658 | 0.80 | ATM (0.39) | ATMMAPTALDH1A1MCL1CES2 | |
| SCHEMBL359232 | 0.80 | ATM (0.52) | ATMMAPTALDH1A1MCL1CES2 | |
| SCHEMBL9841858 | 0.77 | ALDH1A1 (0.41) | ATMMAPTALDH1A1MCL1CES2 | |
| SCHEMBL8934766 | 0.76 | CA2 (0.61) | ATMMAPTALDH1A1MCL1CES2 | |
| SCHEMBL16308964 | 0.76 | ATM (0.48) | ATMMAPTALDH1A1MCL1CES2 | |
| SCHEMBL14081321 | 0.76 | ATM (0.48) | ATMMAPTALDH1A1MCL1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | KAHRS, Bjoern Colin (CH) | 2023-06-22 | — | — | US | disclosed |
| US-10426763-B2 | Pharmaceutical compositions comprising glitazones and NRF2 activators | Kahrs, Bjoern Colin (CH) | 2019-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426763-B2 | Pharmaceutical compositions comprising glitazones and NRF2 activators | PPARG, PPARA, PPARD | ATM 3808/4885MAPT 1063/4885ALDH1A1 838/4885 |
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | ATM 3808/4885MAPT 1063/4885ALDH1A1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.